Bolus infusion of clotting factor concentrates remains the most common approach to the treatment or prevention of bleeding in patients with hemophilia. Although successful use of continuous infusion of such concentrates has been reported by several groups, this alternative treatment method has not achieved widespread popularity. We report here our experience in one hemophilia center with the use of continuous infusion of factor Vlll and factor IX concentrates in 13 patients, 11 with hemophilia A, and 2 with hemophilia 6. All patients were treated successfully for bleeding episodes (e.g., hemarthroses, intracranial, or gastrointestinal bleeding) or for surgical procedures (appendectomy, thoracotomy, etc.). Three patients with low titer factor Vlll inhibitors were treated successfully with constant infusion therapy, requiring a mean dose of factor Vlll concentrate 2.3 fold (8.20 ulkglh) higher than that of the patients without inhibitors (3.63 ulkglh) to maintain a circulating plasma level of factor Vlll of 1 ulml.
The use of constant infusion of clotting factor concentrates is safe, efficacious, and more convenient than bolus therapy of factor concentrates and should be considered for hospitalized hemophilia patients requiring replacement therapy.